Enabling in-house comprehensive genomic profiling (CGP) to meet increasingly clinical oncology needs

Join us at Illumina booth 800 to learn how Illumina is driving innovation in cancer research and clinical solutions.

Liquid biopsy allows non-invasive detection and analysis of tumor-derived biomarkers in body fluids like blood, urine, and saliva, aiding in early detection, therapy selection, and disease monitoring. Liquid biopsy has the potential to expands access to precision medicine in cases where tissue biopsies are unavailable, have low tumor content or fail quality control metrics. Illumina’s broad liquid biopsy portfolio includes Pillar small panels, TruSight Oncology500 ctDNA v2 for comprehensive genomic profiling, and even exome and whole genome sequencing. Find out how Illumina’s library prep uses dual-strand unique molecular indexing (UMIs) and the DRAGEN enrichment pipeline, to minimize the risk of false positive, and lower the limit of detection while maintaining high specificity